Last updated: 2026-09-22 23:13:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Viking Therapeutics, Inc. (VKTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $40,86, with a market capitalization of $3,38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $24,52 to $45,61. This page covers its latest market performance, valuation, price trends and company information.
$3,38B | |
$37,00 | |
$99,41 | |
$0,88 | |
$30,11 | |
40,23M | |
2,29M | |
-- | |
$45,61 | |
$24,52 | |
-- | |
-- |
Viking Therapeutics, Inc. (VKTX) is trading at $41,73 in after-hours trading as of 2026-09-22 23:11:00, up 38,58% ($11,62) from the regular-session close of $30,11.
After-hours trading shows how investors are pricing VKTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Viking Therapeutics, Inc. (VKTX) moved from $31,98 to $40,86, representing a gain of 27,78% ($8,88).
The stock traded between $28,40 and $45,61 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2,82 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77,5%
VKTX is currently trading at $40,86, placing it 77,5% of the way from its 52-week low of $24,52 to its 52-week high of $45,61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Viking Therapeutics, Inc. (VKTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.